All Outputs (3)

Distinct immune regulatory receptor profiles linked to altered monocyte subsets in sarcoidosis (2020)
Journal Article
Fraser, S. D., Crooks, M. G., Kaye, P. M., & Hart, S. P. (2021). Distinct immune regulatory receptor profiles linked to altered monocyte subsets in sarcoidosis. ERJ Open Research, 7(1), https://doi.org/10.1183/23120541.00804-2020

Background: In sarcoidosis, blood monocytes, circulating precursors of granuloma macrophages, display enhanced inflammatory cytokine production, reduced expression of the regulatory (inhibitory) receptor CD200R, and altered subsets defined by CD14 an... Read More about Distinct immune regulatory receptor profiles linked to altered monocyte subsets in sarcoidosis.

Azithromycin for sarcoidosis cough: an open label exploratory clinical trial (2020)
Journal Article
Fraser, S. D., Thackray-Nocera, S., Shepherd, M., Flockton, R., Wright, C., Sheedy, W., Brindle, K., Morice, A. H., Kaye, P. M., Crooks, M. G., & Hart, S. P. (2020). Azithromycin for sarcoidosis cough: an open label exploratory clinical trial. ERJ Open Research, 6(4), Article 00534. https://doi.org/10.1183/23120541.00534-2020

Background: Chronic cough is a distressing symptom for many people with pulmonary sarcoidosis. Continuous treatment with a macrolide antibiotic may improve cough. We aimed to assess the potential efficacy of azithromycin in patients with sarcoidosis... Read More about Azithromycin for sarcoidosis cough: an open label exploratory clinical trial.

Randomised, double-blind, multicentre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B feasibility) (2020)
Journal Article
Higginson, I., Wilcock, A., Johnson, M. J., Bajwah, S., Lovell, N., Yi, D., Hart, S., Crosby, V., Poad, H., Currow, D., Best, E., & Brown, S. (2020). Randomised, double-blind, multicentre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B feasibility). Thorax, 75(2), 176-179. https://doi.org/10.1136/thoraxjnl-2019-213879

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. New treatments are required for severe breathlessness in advanced disease. We conducted a randomised feasibility trial of mirtazapine over 28 days in adults with... Read More about Randomised, double-blind, multicentre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B feasibility).